Published in Am J Gastroenterol on March 01, 1991
Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease. Proc Natl Acad Sci U S A (1992) 2.18
Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol (2006) 1.25
Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol (2005) 1.22
Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer (2006) 1.18
Hepatitis C virus RNA in southern African blacks with hepatocellular carcinoma. Proc Natl Acad Sci U S A (1993) 1.12
Proanthocyanidin from blueberry leaves suppresses expression of subgenomic hepatitis C virus RNA. J Biol Chem (2009) 1.04
Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors. Nucleic Acids Res (2008) 1.04
Mortality related to sexually transmitted diseases in US women, 1973 through 1992. Am J Public Health (1997) 0.96
Detection of replicative hepatitis C virus sequences in hepatocellular carcinoma. Am J Pathol (1992) 0.95
Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase. Antimicrob Agents Chemother (2014) 0.95
Evidence for hepatitis C viral infection in patients with primary hepatocellular carcinoma. West J Med (1994) 0.92
Detection of hepatitis B and C viruses in almost all hepatocytes by modified PCR-based in situ hybridization. J Clin Microbiol (2010) 0.88
A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. J Surg Res (2008) 0.88
Mutations in a hydrophilic part of the core gene of hepatitis C virus in patients with hepatocellular carcinoma in China. J Gastroenterol (1997) 0.88
Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. Dig Dis Sci (2001) 0.86
Structure-based virtual screening, synthesis and SAR of novel inhibitors of hepatitis C virus NS5B polymerase. Bioorg Med Chem (2010) 0.84
Hepatocellular carcinoma in Lebanon: Etiology and prognostic factors associated with short-term survival. World J Gastroenterol (2006) 0.84
Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis (2011) 0.84
Molecular typing of hepatitis C virus genome from sera and liver tissues of patients with anti-HCV positive chronic liver disease. Korean J Intern Med (1993) 0.82
Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy. World J Gastroenterol (2005) 0.81
Hepatitis B virus gene in liver tissue promotes hepatocellular carcinoma development in chronic hepatitis C patients. Dig Dis Sci (2003) 0.81
Autophagy in hepatitis C virus-host interactions: potential roles and therapeutic targets for liver-associated diseases. World J Gastroenterol (2014) 0.80
Identification of HCV genotypes in HCV infected blood donors. Indian J Microbiol (2010) 0.78
Hepatocellular carcinoma: clinicopathological profile and challenges of management in a resource-limited setting. World J Surg Oncol (2014) 0.76
Epidemiology of hepatitis C virus in Ghana: a systematic review and meta-analysis. BMC Infect Dis (2016) 0.76
Synthesis and SAR optimization of diketo acid pharmacophore for HCV NS5B polymerase inhibition. Eur J Med Chem (2011) 0.75
Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science (1989) 37.89
An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science (1989) 18.79
Binding of hepatitis C virus to CD81. Science (1998) 12.40
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Detection of hepatitis C viral sequences in non-A, non-B hepatitis. Lancet (1990) 8.56
Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med (1989) 8.10
Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology (1994) 7.89
Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature (1986) 7.38
Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease. Hepatology (1991) 7.33
Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end. Proc Natl Acad Sci U S A (1991) 7.13
Analysis of a successful immune response against hepatitis C virus. Immunity (1999) 6.31
Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med (2000) 5.27
Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology (1991) 4.47
A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. Nucleic Acids Res (1989) 4.29
Antibody to hepatitis-B-virus core in man. Lancet (1973) 4.24
Management of hepatitis B: 2000--summary of a workshop. Gastroenterology (2001) 4.17
Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull (1990) 4.16
On the role of sexual behavior in the spread of hepatitis B infection. Ann Intern Med (1975) 4.11
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest (1996) 4.10
Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A (1994) 3.76
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest (1995) 3.47
Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med (1989) 3.45
The successful control of burn wound sepsis. J Trauma (1965) 3.43
Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet (1989) 3.42
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med (1995) 3.32
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A (1996) 3.25
Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A (1995) 3.20
Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome. J Gen Virol (1993) 3.18
Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol (1992) 3.13
Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med (1990) 2.99
A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta. J Virol (1988) 2.99
NIH conference. Hepatocellular carcinoma. Ann Intern Med (1988) 2.94
Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med (1986) 2.85
Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers. Nucleic Acids Res (1990) 2.76
The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. Biochem Biophys Res Commun (1993) 2.67
HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest (1995) 2.66
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest (1996) 2.65
Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses. J Virol (1993) 2.58
Characterization of the hepatitis C virus E2/NS1 gene product expressed in mammalian cells. Virology (1992) 2.58
Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV. J Virol (1993) 2.57
At least five related, but distinct, hepatitis C viral genotypes exist. Proc Natl Acad Sci U S A (1992) 2.56
The presence of ovalbumin mRNA coding sequences in multiple restriction fragments of chicken DNA. Nucleic Acids Res (1977) 2.52
Long-term therapy of chronic hepatitis B with lamivudine. Hepatology (2000) 2.49
Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1995) 2.49
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol (1996) 2.47
Hepatitis C antibody and chronic liver disease in haemophilia. Lancet (1990) 2.44
Experimental infection of chimpanzees with hepatitis A virus. J Infect Dis (1975) 2.41
T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology (1993) 2.39
Genotypic analysis of hepatitis C virus in American patients. Hepatology (1994) 2.33
Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol (2000) 2.32
Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med (1978) 2.30
Complex processing and protein:protein interactions in the E2:NS2 region of HCV. Virology (1994) 2.27
Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology (1991) 2.25
Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation (2000) 2.25
Structure of two related rat pancreatic trypsin genes. J Biol Chem (1984) 2.24
Measurements of iron status in patients with chronic hepatitis. Gastroenterology (1992) 2.22
Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther (2014) 2.19
Diagnosis of hepatitis C virus (HCV) infection using an immunodominant chimeric polyprotein to capture circulating antibodies: reevaluation of the role of HCV in liver disease. Proc Natl Acad Sci U S A (1992) 2.18
Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology (1991) 2.15
Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci U S A (1990) 2.12